A phase 3, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

Next Previous
Trial Profile

A phase 3, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Peretinoin (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Kowa

    • Most Recent Events

    • 09 Jan 2018 Planned End Date changed from 30 Mar 2018 to 31 Jan 2019.
    • 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top